Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome

Lauren W. Wood, Nicole I. Cox, Cody A. Phelps, Shao Chiang Lai, Arjun Poddar, Conover Talbot, David Mu

Research output: Contribution to journalArticlepeer-review

Abstract

Through both gain- and loss-of-TTF-1 expression strategies, we show that TTF-1 positively regulates vascular endothelial growth factor (VEGF) and that the VEGF promoter element contains multiple TTF-1-responsive sequences. The major signaling receptor for VEGF, i.e VEGFR2, also appears to be under a direct and positive regulation of TTF-1. The TTF-1-dependent upregulation of VEGF was moderately sensitive to rapamycin, implicating a partial involvement of mammalian target of rapamycin (mTOR). However, hypoxia did not further increase the secreted VEGF level of the TTF-1+ lung cancer cells. The TTF-1-induced VEGF upregulation occurs in both compartments (exosomes and exosome-depleted media (EDM)) of the conditioned media. Surprisingly, the EDM of TTF-1+ lung cancer cells (designated EDM-TTF-1 +) displayed an anti-angiogenic activity in the endothelial cell tube formation assay. Mechanistic studies suggest that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in the EDM-TTF-1+ conferred the antiangiogenic activities. In human lung cancer, the expression of TTF-1 and GM-CSF exhibits a statistically significant and positive correlation. In summary, this study provides evidence that TTF-1 may reprogram lung cancer secreted proteome into an antiangiogenic state, offering a novel basis to account for the long-standing observation of favorable prognosis associated with TTF-1+ lung adenocarcinomas.

Original languageEnglish (US)
Article number19857
JournalScientific reports
Volume6
DOIs
StatePublished - Feb 25 2016

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome'. Together they form a unique fingerprint.

Cite this